RT Journal Article
SR Electronic
T1 High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge: a case for continued use of masks post-vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.28.21252621
DO 10.1101/2021.02.28.21252621
A1 Ujjainiya, Rajat
A1 Tyagi, Akansha
A1 Sardana, Viren
A1 Naushin, Salwa
A1 Bhatheja, Nitin
A1 Kumar, Kartik
A1 Barman, Joydeb
A1 Prakash, Satyartha
A1 Kutum, Rintu
A1 Bhaskar, Akash K
A1 Singh, Prateek
A1 Chaudhary, Kumardeep
A1 Loomba, Menka
A1 Khanna, Yukti
A1 Walecha, Chestha
A1 Ahmed, Rizwan
A1 Yadav, Ashutosh
A1 Bajaj, Archana
A1 Malik, Gaurav
A1 Qureshi, Sahar
A1 Waghdhare, Swati
A1 Siddiqui, Samreen
A1 Trehan, Kamal Krishan
A1 Mani, Manju
A1 Dang, Rajiv
A1 Das, Poonam
A1 Dougall, Pankaj
A1 Mahajan, Monica
A1 Sonar, Sudipta
A1 Jakhar, Kamini
A1 Kumar, Reema
A1 Tiwari, Mahima
A1 Mani, Shailendra
A1 Bhattacharyya, Sankar
A1 Budhiraja, Sandeep
A1 Agrawal, Anurag
A1 Dash, Debasis
A1 Jha, Sujeet
A1 Sengupta, Shantanu
YR 2021
UL http://medrxiv.org/content/early/2021/08/28/2021.02.28.21252621.abstract
AB Immunization is expected to confer protection against infection and severe disease for vaccinees, while reducing risks to unimmunized populations by inhibiting transmission. Here, based on serial serological studies, we show that during a severe SARS-CoV2 Delta-variant outbreak in Delhi, 25.3% (95% CI 16.9 - 35.2) of previously uninfected, ChAdOx1-nCoV19 double vaccinated, healthcare-workers (HCW) were infected within a period of less than two months, based on serology. Induction of anti-spike response was similar between groups with breakthrough infection (541 U/ml, IQR 374) or not (342 U/ml, IQR 497), as was induction of neutralization activity to wildtype. Most infections were unrecognized. The Delta-variant thus causes frequent unrecognized breakthrough infections in adequately immunized subjects, reducing any herd-effect of immunity, and requiring reinstatement of preventive measures such as masking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Ethics Committee (Max healthcare Committee), New Delhi with separate approval for all sites and CSIR-IGIB, New Delhi IHECAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for de-identified data may be send to the corresponding authors stating end usage. Data will be shared on request basis.